Vaid, Akhil http://orcid.org/0000-0002-3343-744X
Jiang, Joy
Sawant, Ashwin http://orcid.org/0000-0003-1525-8541
Lerakis, Stamatios
Argulian, Edgar
Ahuja, Yuri
Lampert, Joshua
Charney, Alexander http://orcid.org/0000-0001-8135-6858
Greenspan, Hayit
Narula, Jagat
Glicksberg, Benjamin http://orcid.org/0000-0003-4515-8090
Nadkarni, Girish N http://orcid.org/0000-0001-6319-4314
Article History
Received: 13 January 2023
Accepted: 5 May 2023
First Online: 6 June 2023
Competing interests
: Dr. Nadkarni reports consultancy agreements with AstraZeneca, BioVie, GLG Consulting, Pensieve Health, Reata, Renalytix, Siemens Healthineers, and Variant Bio; research funding from Goldfinch Bio and Renalytix; honoraria from AstraZeneca, BioVie, Lexicon, Daiichi Sankyo, Meanrini Health and Reata; patents or royalties with Renalytix; owns equity and stock options in Pensieve Health and Renalytix as a scientific cofounder; owns equity in Verici Dx; has received financial compensation as a scientific board member and advisor to Renalytix; serves on the advisory board of Neurona Health; and serves in an advisory or leadership role for Pensieve Health and Renalytix. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.